One study showed that liraglutide, a GLP-1 receptor agonist approved for human T2D and obesity, improved glycemic control during hyperglycemia in healthy cats by increasing insulin concentrations and decreasing glucagon concentrations. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.